Seelos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019年8月15日 - 7:00AM
Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage
biopharmaceutical company, announced today that it has granted a
stock option to purchase 97,285 shares of common stock to Warren
Wasiewski, MD, Seelos’ newly appointed Chief Scientific
Officer. This inducement award was granted pursuant to the
Seelos Therapeutics, Inc. 2019 Inducement Plan, approved by the
compensation committee of Seelos’ board of directors on July 28,
2019 and granted as an inducement material to Dr. Wasiewski’s
employment with Seelos in accordance with Nasdaq Listing Rule
5635(c)(4).
The stock option has an exercise price equal to $1.60, the
closing price per share of Seelos’ common stock as reported by
Nasdaq on August 12, 2019, the date of grant. The option is a
non-qualified stock option and 1/4th of the shares vest on the
one-year anniversary of Dr. Wasiewski’s commencement of employment
and an additional 1/48th of the shares vest monthly thereafter over
the next three years, in each case provided that Dr. Wasiewski
remains continuously employed by Seelos through the applicable
vesting date, inclusive.
Seelos is providing this information in accordance with Nasdaq
Listing Rule 5635(c)(4).
About Seelos Therapeutics:
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development and advancement of novel
therapeutics to address unmet medical needs for the benefit of
patients with central nervous system (CNS) disorders and other rare
disorders. The Company's robust portfolio includes several
late-stage clinical assets targeting psychiatric and movement
disorders, including orphan diseases. Seelos is based in New York,
New York. For more information, please visit our website:
http://seelostherapeutics.com, the content of which is not
incorporated herein by reference.
Forward-Looking Statements:
This press release contains forward-looking statements subject
to risks and uncertainties that could cause actual results to
differ materially from those projected. Forward-looking statements
include statements about the employees and equity plans. Risks and
uncertainties include risks associated with the Company’s employees
and equity plans, and additional risks set forth in the Company's
filings with the Securities and Exchange Commission. These
forward-looking statements represent the Company's judgment as of
the date of this release. The Company disclaims, however, any
intent or obligation to update these forward-looking
statements.
Contact Information: Anthony Marciano Head of Corporate
Communications Seelos Therapeutics, Inc. (NASDAQ: SEEL) 300 Park
Ave., 12th Fl New York, NY 10022 (646) 293-2136
anthony.marciano@seelostx.com www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
Seelos Therapeutics (NASDAQ:SEEL)
過去 株価チャート
から 6 2024 まで 7 2024
Seelos Therapeutics (NASDAQ:SEEL)
過去 株価チャート
から 7 2023 まで 7 2024